Vertex Pharmaceuticals Q3 Revenue Up 12% · Annual Guidance Raised
VRTX Vertex Pharmaceuticals Inc
$547.09 +0.85%
View chart & analysis → 
- 1Vertex Pharmaceuticals' total revenue increased by 12% year-over-year in the third quarter.
- 2Vertex Pharmaceuticals' annual revenue guidance range was raised to $13.15 billion to $13.25 billion.
- 3The acquisition of Crinetics Pharmaceuticals via a net cash transaction is $9 billion.
So what's the key point?
Vertex Pharmaceuticals' third-quarter revenue grew by 12%. The company has raised its expected earnings for the year.
Source The Motley Fool +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.